nach oben

Current Pediatrics Reports

Erschienen in:

01.09.2020 | Renal (D Noone, Section Editor)

Medication-Induced Nephrotoxicity in Children

verfasst von: James Tjon, Chia Wei Teoh

Erschienen in: Current Pediatrics Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this article is to review common mechanisms of drug-induced nephrotoxicity (DIN) while highlighting some of the common medications in each category, as well as risk factors and preventative strategies with a focus on mitigating the risks of kidney injury with the use of potentially nephrotoxic medications in children.

Recent Findings

There have been recent reports about DIN associated with well-established and newer medications based on pathogenic mechanisms, new biomarkers being researched to identify DIN, and the recent development of standardized phenotypes to characterize DIN.

Summary

The kidney is a common site of drug toxicity and can occur in all age groups, including children, although the body of evidence characterizing DIN is limited compared with adults. Several drugs and drug classes can cause nephrotoxicity by one or more mechanisms. It is important for clinicians to recognize the risks for development of DIN so that appropriate monitoring and preventative measures can be implemented when the use of potentially nephrotoxic medications is necessary.

Sekine T: Nephrotoxins and pediatric kidney injury. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Emma F, Goldstein SL, editors. Pediatric nephrology, 7th edition. Springer Reference; 2016.

Perazella M. Drug-induced nephropathy: an update. Expert Opin Drug Saf. 2005;4(4):689–706.PubMed

Fanos V, Cuzzolin L. Causes and manifestation of nephrotoxicity. In: Geary DF, Schaefer F, editors. Comprehensive pediatric nephrology, 1st edition. Mosby Elsevier; 2008.

• Perazella M. Pharmacology behind common drug nephrotoxicities. Clin J Am Soc Nephrol. 2018;13:1897–908. https://doi.org/10.2215/CJN.00150118A thorough review of pharmacological and clinical aspects of DIN. CrossRefPubMedPubMedCentral

Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephol Renovasc Dis. 2014;7:457–68. https://doi.org/10.2147/IJNRD.S39747.CrossRef

Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clin J Am Soc Nephrol. 2011;6:856–63. https://doi.org/10.2215/CJN.08110910.CrossRefPubMedPubMedCentral

Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol. 2008;23:2159–73. https://doi.org/10.1007/s00467-007-0721-x.CrossRefPubMedPubMedCentral

• Hanna MH, Askenazi DJ, Selewski DT. Drug-induced acute kidney injury in neonates. Curr Opin Pediatr. 2016;28(2):180–7. https://doi.org/10.1097/MOP.0000000000000311A solid review of drug-induced AKI in neonates. CrossRefPubMedPubMedCentral

•• Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226–34. https://doi.org/10.1038/ki.2015.115A consensus-based approach to developing standardized phenotypes to characterize drug-induced kidney disease. CrossRefPubMedPubMedCentral

10.

• Faria J, Ahmed S, Gerritsen KGF, Mihaila SM, Masereeuw R. Kidney-based in vitro models for drug- induced toxicity testing. Arch Toxicol. 2019;93:3397–418. https://doi.org/10.1007/s00204-019-02598-0An article describing in vitro models for drug-induced nephrotoxicity. CrossRefPubMed

11.

Nolin TD, Himmelfarb J. Drug-induced kidney disease. In: DiPiro J, Talbert RL, Yee G, Matzke G, Wells B, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach, 8th edition. McGraw-Hill Medical 2011.

12.

Hilgers KF, Dotsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol. 2004;19:956–61.PubMed

13.

Hsu CY, Liu KD, Yang J, Glidden DV, Tan TC, Pravoverov L, et al. Renin-angiotensin system blockade after acute kidney injury (AKI) and risk of recurrent AKI. CJASN. 2020;15(1):26–34. https://doi.org/10.2215/CJN.05800519.CrossRefPubMed

14.

Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13S–24S.PubMed

15.

John CM, Shukla R, Jones CA. Using NSAID in volume depleted children can precipitate acute renal failure. Arch Dis Child. 2007;92:524–6.PubMedPubMedCentral

16.

Moghal NE, Hegde S, Eastham KM. Ibuprofen and acute renal failure in a toddler. Arch Dis Child. 2004;89:276–7.PubMedPubMedCentral

17.

Ulinski T, Guigonis V, Dunan O, Bensman A. Acute renal failure after treatment with non-steroidal inflammatory drugs. Eur J Pediatr. 2004;163:148–50.PubMed

18.

Krause I, Cleper R, Eisenstein B, Davidovits M. Acute renal failure, associated with non-steroidal anti- inflammatory drugs in healthy children. Pediatr Nephrol. 2005;20:1295–8.PubMed

19.

Balestracci A, Ezquer M, Elmo ME, Molini A, Thorel C, Torrents M, et al. Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis. Pediatr Nephrol. 2015;30(10):1873–8. https://doi.org/10.1007/s00467-015-3105-7.CrossRefPubMed

20.

Fletcher JT, Graf N, Searman A, Saleh H, Alexander SI. Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatr Nephrol. 2006;21:1893–7. https://doi.org/10.1007/s00467-006-0252-x.CrossRefPubMed

21.

Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc. 2004;36:220S–3S.PubMed

22.

Busauschina A, Schnuelle P, Van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc. 2004;36:229S–33S.PubMed

23.

Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–76.PubMed

24.

de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35(2):333–46.PubMed

25.

Medeiros M, Castañeda-Hernández G, Ross CJD, Carleton BC. Use of pharmacogenomics in pediatric renal transplant recipients. Front Genet. 2015;6(41):1–9.

26.

• McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol. 2017;32:2015–25. https://doi.org/10.1007/s00467-016-3533-zAn updated review of aminoglycoside-induced nephrotoxicity in children. CrossRefPubMed

27.

•• Downes KJ, Hayes M, Fitzgerald JC, Pais GM, Liu J, Zane NR et al. Mechanisms of antimicrobial-induced nephrotoxicity in children. J Antimicrob Chemother 2019. pii: dkz325. doi:https://doi.org/10.1093/jac/dkz325. An extensive and updated review of mechanisms of antimicrobial induced nephrotoxicity with focus on pediatrics.

28.

Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside adminishtration for cildren: a meta-analysis. Pediatrics. 2004;114:e111–8.PubMed

29.

Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–5.PubMedPubMedCentral

30.

Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1991;341:335–9.

31.

Bhatt J, Jahnke N, Smyth AR. Once-daily dosing versus multiple-daily dosing of intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2019;9:CD002009. https://doi.org/10.1002/14651858.CD002009.pub7.CrossRefPubMed

32.

McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. 66 Association of urinary kidney injury molecule-1 with aminoglycoside exposure in children with cystic fibrosis. J Cyst Fibros. 2014;13:S63.

33.

Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol. 2004;26(7):421–6.PubMed

34.

Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, Soldin S, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988;113:559–63.PubMed

35.

Bes DF, Rosanova MT, Sherna N, Arrizurieta E. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. Pediatr Infect Dis. 2014;33:e198–206.

36.

Goldman RD, Ong M, Wolpin J, Doyle J, Parshuram C, Koren G. Pharmacological risk factors for amphotericin B nephrotoxicity in children. J Clin Pharmacol. 2007;47:1049–54.PubMed

37.

Blyth C, Hale K, Palasanthiran P, O’Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010:CD006343. doi: https://doi.org/10.1002/14651858.CD006343.pub2.

38.

Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11(1):177–82.PubMed

39.

Bianchetti MG, Roduitt C, Oetliker OH. Acyclovir-induced renal failure: course and risk factors. Pediatr Nephrol. 1991;5(2):238–9.PubMed

40.

Schreiber R, Wolpin J, Koren G. Determinants of acyclovir-induced nephrotoxicity in children. Pediatr Drugs. 2008;10(2):135–9.

41.

Rao S, Abzug MJ, Carosone-Link P, Peterson T, Child J, Siparksy G, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study. J Pediatr. 2015;166:1462–8.e1–4. https://doi.org/10.1016/j.jpeds.2015.01.023.CrossRefPubMed

42.

Xing W, Gu L, Zhang X, Xu J, Lu H. A metabolic profiling analysis of the nephrotoxicity of acyclovir rats using ultra performance liquid chromatography/mass spectrometry. Environ Toxicol Pharmacol. 2016;46:234–40.PubMed

43.

Ahmad T, Simmonds M, McIver AG, McGraw ME. Reversible renal failure in transplant patients receiving oral acyclovir prophylaxis. Pediatr Nephrol. 1994;8:489–91.PubMed

44.

Vomeiro G, Carpenter B, Robb I, Filler G. Combination of ceftriaxone and acyclovir – an underestimated nephrotoxic potential? Pediatr Nephrol. 2002;17:633–7.

45.

Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 1991;41(1):104–29.PubMed

46.

Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity. Ann Intern Med. 1990 Aug 15;113(4):332.PubMed

47.

Vora SB, Brothers AW, Englund JA. Renal toxicity in pediatric patients receiving cidofovir for the treatment of adenovirus infection. J Pediatric Infect Dis Soc. 2017;6(4):399–402. https://doi.org/10.1093/jpids/pix011.CrossRefPubMed

48.

Anderson EJ, Guzman-Cottrill JA, Kletzel M, Thormann K, Sullivan C, Zheng X, et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008;12(2):219–27. https://doi.org/10.1111/j.1399-3046.2007.00851.x.CrossRefPubMed

49.

• Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol. 2017;83(12):2605–14. https://doi.org/10.1111/bcp.13388A current and solid overview of chemotherapy-induced renal disease in children. CrossRefPubMedPubMedCentral

50.

Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity: insights into mechanism. Int J Androl. 1987 Feb;10(1):325–46.PubMed

51.

Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2013;10:CD008944. https://doi.org/10.1002/14651858.CD008944.pub2.CrossRef

52.

Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, et al. Platinum compounds in children with cancer: toxicity and clinical management. Anti-Cancer Drugs. 2013;24(10):1007–19. https://doi.org/10.1097/CAD.0b013e3283650bda.CrossRefPubMed

53.

Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol. 1997;28(1):35–40.PubMed

54.

Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer. 2001;84(8):1029–35.PubMedPubMedCentral

55.

• Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol. 2015;10(7):1291–9. https://doi.org/10.2215/CJN.00860115A current and interesting review of drug-induced glomerular disease. CrossRefPubMedPubMedCentral

56.

Kala GK, Mogri M, Weber-Shrikant E, Springate JE. Lithium-induced membranous glomerulonephropathy in a pediatric patient. Pediatr Nephrol. 2009;24(11):2267–9. https://doi.org/10.1007/s00467-009-1245-3.CrossRefPubMed

57.

Sakarcan A, Thomas DB, O’Reilly KP, Richards RW. Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr Nephrol. 2002;17(4):290–2.PubMed

58.

Izzedine H, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G. Drug-induced glomerulopathies. Expert Opin Drug Saf. 2006;5(1):95–106.PubMed

59.

Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol. 2006;1(4):655–67.PubMed

60.

• Joyce E, Glasner P, Ranganathan S, Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr Nephrol. 2017;32(4):577–87. https://doi.org/10.1007/s00467-016-3394-5An updated review of tubulointerstitial nephritis. CrossRefPubMed

61.

Krishnan N, Perazella MA. Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. Iran J Kidney Dis. 2015;9(1):3–13.PubMed

62.

Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci. 2003;325(6):349–62.PubMed

63.

Ellis D, Fried WA, Yunis EJ, Blau EB. Acute interstitial nephritis in children: a report of 13 cases and review of the literature. Pediatrics. 1981;67(6):862–70.PubMed

64.

Papachristou F, Printza N, Farmaki E, Leontsini M, Kavaki D, Kollios K. Antibiotics-induced acute interstitial nephritis in 6 children. Urol Int. 2006;76(4):348–52.PubMed

65.

Dixit MP, Nguyen C, Carson T, Guedes B, Dixit NM, Bell JM, et al. Non-steroidal anti-inflammatory drugs-associated acute interstitial nephritis with granular tubular basement membrane deposits. Pediatr Nephrol. 2008;23(1):145–8.PubMed

66.

Martínez López AB, Álvarez Blanco O, de Pablos Luque A, Morales San-José MD, de la Blanca Rodríguez Sanchez A. Ibuprofen-induced acute interstitial nephritis in the paediatric population. Nefrologia. 2016;36(1):69–71. https://doi.org/10.1016/j.nefro.2015.09.003.CrossRefPubMed

67.

Noone D, Teoh CW, Dorman AM, Awan A. Omeprazole induced acute interstitial nephritis in an adolescent. J Nephrol Ther. 2014;4:3. https://doi.org/10.4172/2161-0959.1000159.CrossRef

68.

Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol. 2017;12(12):2046–9. https://doi.org/10.2215/CJN.07630717.CrossRefPubMedPubMedCentral

69.

Eddy AA. Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways. Pediatr Nephrol. 2020;35(4):547–54. https://doi.org/10.1007/s00467-019-04207-9.CrossRefPubMed

70.

Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–50.PubMed

71.

Silva FG. Chemical-induced nephropathy: a review of the renal tubulointerstitial lesions in humans. Toxicol Pathol. 2004;32(Suppl 2):71–84.PubMed

72.

Yang B, Xie Y, Guo M, Rosner MH, Yang H, Ronco C. Nephrotoxicity and Chinese herbal medicine. Clin J Am Soc Nephrol. 2018;13:1605–11. https://doi.org/10.2215/CJN.11571017.CrossRefPubMedPubMedCentral

73.

Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 1988;33(2):590–600.PubMed

74.

Loo RM, Ariyarajah V, Oh C, Shen L, Aw MM, Prabhakaran K. Comparison between effects of cyclosporine and tacrolimus on glomerular filtration rate in pediatric post-orthotopic liver transplant patients. Pediatr Transplant. 2006;10(1):55–9.PubMed

75.

Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child. 2006;91(8):666–70.PubMedPubMedCentral

76.

Fujinaga S, Urushihara Y. Impact of interrupted cyclosporine treatment on the development of chronic nephrotoxicity in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2017;32(8):1469–70. https://doi.org/10.1007/s00467-017-3692-6.CrossRefPubMed

77.

Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, et al. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013;24(11):1849–62. https://doi.org/10.1681/ASN.2012111064.CrossRefPubMedPubMedCentral

78.

Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–33.PubMed

79.

Gupta N, Gibson M, Wallace EC. Lithium-induced chronic kidney disease in a pediatric patient. Case Rep Pediatr. 2019;5406482:1–4. https://doi.org/10.1155/2019/5406482.CrossRef

80.

Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: unravelling the complex pathophysiological threads of the lightest metal. Nephrology. 2018;23:897–903. https://doi.org/10.1111/nep.13263.CrossRefPubMed

81.

Presne C, Fakhouri F, Noël LH, Stengel B, Even C, Kreis H, et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int. 2003;64(2):585–92.PubMed

82.

Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–65.PubMed

83.

Fogazzi GB. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant. 1996;11(2):379–87.PubMed

84.

Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001;24(7):491–501.PubMed

85.

Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005;31(6):681–90.PubMed

86.

Radhakrishnan J, Perazella MA. Drug-induced glomerular disease: attention required! Clin J Am Soc Nephrol. 2015;10(7):1287–90. https://doi.org/10.2215/CJN.01010115.CrossRefPubMedPubMedCentral

87.

Hebert SA, Bohan TP, Erikson CL, Swinford RD. Thrombotic microangiopathy associated with valproic acid toxicity. BMC Nephrol. 2017;18(1):262. https://doi.org/10.1186/s12882-017-0677-4.CrossRefPubMedPubMedCentral

Titel: Medication-Induced Nephrotoxicity in Children
verfasst von: James Tjon
Chia Wei Teoh
Publikationsdatum: 01.09.2020
Verlag: Springer US
Erschienen in: Current Pediatrics Reports / Ausgabe 3/2020
Elektronische ISSN: 2167-4841
DOI: https://doi.org/10.1007/s40124-020-00223-8

Neu im Fachgebiet Pädiatrie

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Medication-Induced Nephrotoxicity in Children

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Pädiatrie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update Pädiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Advances and Current Issues in Adolescent Sleep

Pediatric Delirium: a Review of Current Diagnosis and Management in the Intensive Care Setting

Preparing the Child with End-Stage Renal Disease for a Renal Transplant: the Pre-transplant Assessment

Cyberbullying and Adolescents

New Decade: “New” Devices for “Old” Drugs

The Future of Paediatric Nephrology—Genomics and Personalised Precision Medicine

Neu im Fachgebiet Pädiatrie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update Pädiatrie